ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,537.02
      0.51%
      US Tech 100
      19,634.80
      0.80%
      Dow Jones
      39,308.00
      -0.06%
      Brent Oil
      86.74
      -0.20%
      Bitcoin
      58,657.87
      -2.50%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Regeneron Pharmaceuticals Inc (REGN)

      7. Regeneron Pharmaceuticals Inc (REGN) News

      REGN

      Regeneron Pharmaceuticals (REGN)

      Regeneron Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:REGN
      DateTimeSourceHeadlineSymbolCompany
      1:00PMiHub NewswireFeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent
      02/26/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/26/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/26/20244:07PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/26/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/26/20243:25PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/23/20244:04PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/23/20241:00AMGlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 InflammationNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/22/20245:10PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/22/20244:06PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/21/20247:00AMGlobeNewswire Inc.Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority ReviewNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/20/20244:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/16/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/16/202412:59AMGlobeNewswire Inc.Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)NASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/14/20245:08PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/12/20244:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/12/20244:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/09/20246:19PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/09/20244:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/09/20244:04PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/09/202412:22PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/08/20244:56PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/08/20244:26PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/08/20244:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/08/20244:01PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/07/20245:59PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/07/20245:07PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/07/20244:35PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/06/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      02/06/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:REGN